The cocaine-and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancer

Oncogene

Volumn 31, Issue 30, 2012, Pages 3483-3494

  Brennan, D J ^a   O'connor, D P ^a   Laursen, H ^a   Mcgee, S F ^a   Mccarthy, S ^a   Zagozdzon, R ^a   Rexhepaj, E ^a   Culhane, A C ^b   Martin, F M ^a   Duffy, M J ^a,c   Landberg, G ^d   Ryden, L ^d   Hewitt, S M ^e   Kuhar, M J ^f   Bernards, R ^g   Millikan, R C ^h   Crown, J P ^c   Jirstrom K ^d   Gallagher, W M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d LUND UNIVERSITY   (Sweden)

^e NATIONAL CANCER INSTITUTE   (United States)

^f EMORY UNIVERSITY   (United States)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

^h University of North Carolina at Chapel Hill   (United States)

Author keywords

breast cancer; cocaine and amphetamine regulated transcript; estrogen receptor; prognosis

Indexed keywords

COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; ESTROGEN RECEPTOR ALPHA; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; AGED; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PARACRINE SIGNALING; PATIENT CODING; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; COHORT STUDIES; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; NERVE TISSUE PROTEINS; PROGNOSIS; TAMOXIFEN; TRANSCRIPTION, GENETIC;

EID: 84864344518     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.519     Document Type: Article

References (43)

1. Adriaenssens E, Vanhecke E, Saule P, Mougel A, Page A, Romon R et al. (2008). Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Res 68: 346-351. (Pubitemid 351380059)
2. Arora S, Anubhuti. (2006). Role of neuropeptides in appetite regulation and obesity-a review. Neuropeptides 40: 375-401. (Pubitemid 44773748)
3. Bech P, Winstanley V, Murphy KG, Sam AH, Meeran K, Ghatei MA et al. (2008). Elevated cocaine-and amphetamine-regulated transcript immunoreactivity in the circulation of patients with neuroendocrine malignancy. J Clin Endocrinol Metab 93: 1246-1253. (Pubitemid 351519717)
4. Borgquist S, Jogi A, Ponten F, Ryden L, Brennan DJ, Jirstrom K. (2008). Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. Breast Cancer Res 10: R79.
5. Brennan D, Jirstrom K, Kronblad A, Millikan R, Landberg G, Duffy M et al. (2006). CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 12: 6421-6431. (Pubitemid 44799714)
6. Brennan DJ, O'Connor DP, Rexhepaj E, Ponten F, Gallagher WM. (2010). Antibody-based proteomics: fasT-tracKing molecular diagnostics in oncology. Nat Rev Cancer 10: 605-617.
7. Brennan DJ, Rexhepaj E, O' Brien SL, Mc Sherry E, O'Connor DP, Fagan A et al. (2008). Altered cytoplasmic-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 14: 2681-2689.
8. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, PiccarT-Gebhart MJ. (2008). Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26: 729-735. (Pubitemid 351264385)
9. Chang C, Norris JD, Gron H, Paige LA, Hamilton PT, Kenan DJ et al. (1999). Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. Mol Cell Biol 19: 8226-8239. (Pubitemid 30414017)
10. Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G et al. (2008). A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 14: 1744-1752. (Pubitemid 351469459)
11. Cheng J, Zhang C, Shapiro DJ. (2007). A functional serine 118 phosphorylation site in estrogen receptor-alpha is required for down-regulation of gene expression by 17beta-estradiol and 4-hydroxytamoxifen. Endocrinology 148: 4634-4641. (Pubitemid 47481539)
12. Dolle L, Adriaenssens E, El Yazidi-Belkoura I, Le Bourhis X, Nurcombe V, Hondermarck H. (2004). Nerve growth factor receptors and signaling in breast cancer. Curr Cancer Drug Targets 4: 463-470. (Pubitemid 39304490)
13. Dominguez G. (2006). The CART gene: structure and regulation. Peptides 27: 1913-1918. (Pubitemid 44067285)
14. Dominguez G, Kuhar M. (2004). Transcriptional regulation of the CART promoter in CATH a cells. Brain Res Mol Brain Res 126: 22-29. (Pubitemid 38781160)
15. Douglass J, McKinzie AA, Couceyro P. (1995). PCR differential display identifies a rat brain mRNA that is transcriptionally regulated by cocaine and amphetamine. J Neurosci 15: 2471-2481.
16. EBCTCG (1998). Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351: 1451-1467.
17. EBCTCG (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
18. Elefteriou F, Ahn J, Takeda S, Starbuck M, Yang X, Liu X et al. (2005). Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434: 514-520. (Pubitemid 40477060)
19. Epping MT, Wang L, Plumb JA, Lieb M, Gronemeyer H, Brown R et al. (2007). A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci USA 104: 17777-17782. (Pubitemid 350210911)
20. Goldhirsch A, Glick J, Gelber R, Coates A, Thü rlimann B, Senn H et al. (2005). Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16: 1569-1583. (Pubitemid 41511089)
21. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al. (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years0 adjuvant treatment for breast cancer. Lancet 365: 60-62.
22. Jia J, Chen X, Zhu W, Luo Y, Hua Z, Xu Y. (2008). CART protects brain from damage through ERK activation in ischemic stroke. Neuropeptides 42: 653-661.
23. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, SasaKi H et al. (1995). Activation of the estrogen receptor through phosphorylation by mitogen-activated protein Kinase. Science 270: 1491-1494.
24. Keegan BP, Akerman BL, Pequeux C, North WG. (2006). Provasopressin expression by breast cancer cells: implications for growth and novel treatment strategies. Breast Cancer Res Treat 95: 265-277.
25. Koylu E, Balkan B, Kuhar M, Pogun S. (2006). Cocaine and amphetamine regulated transcript (CART) and the stress response. Peptides 27: 1956-1969. (Pubitemid 44067291)
26. Koylu EO, Couceyro PR, Lambert PD, Ling NC, DeSouza EB, Kuhar MJ. (1997). Immunohistochemical localization of novel CART peptides in rat hypothalamus, pituitary and adrenal gland. J Neuroendocrinol 9: 823-833. (Pubitemid 27488764)
27. Kristensen P, Judge M, Thim L, Ribel U, Christjansen K, Wulff B et al. (1998). Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393: 72-76. (Pubitemid 28240256)
28. Lakatos A, Prinster S, Vicentic A, Hall R, Kuhar M. (2005). Cocaineand amphetamine-regulated transcript (CART) peptide activates the extracellular signal-regulated Kinase (ERK) pathway in AtT20 cells via putative G-protein coupled receptors. Neurosci Lett 384: 198-202. (Pubitemid 40826644)
29. Mantzoros C, Bolhke K, Moschos S, Cramer D. (1999). Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. Int J Cancer 80: 523-526. (Pubitemid 29047515)
30. O0Brien SL, Fagan A, Fox EJ, Millikan RC, Culhane AC, Brennan DJ et al. (2007). CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer 120: 1434-1443. (Pubitemid 46355377)
31. Rogge G, Jones D, Hubert GW, Lin Y, Kuhar MJ. (2008). CART peptides: regulators of body weight, reward and other functions. Nat Rev Neurosci 9: 747-758.
32. Ruscica M, Dozio E, Motta M, Magni P. (2007). Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer. Peptides 28: 426-434. (Pubitemid 46176277)
33. Ryden L, Jonsson P, Chebil G, DufmatsM, Ferno M, Jirstrom K et al. (2005). Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 41: 256-264. (Pubitemid 40136540)
34. Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE, Landberg G. (2003). Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 82: 147-154. (Pubitemid 37521970)
35. Sen A, Lv L, Bello N, Ireland JJ, Smith GW. (2008). Cocaineand amphetamine-regulated transcript accelerates termination of follicle-stimulating hormone-induced extracellularly regulated Kinase 1/2 and AKT activation by regulating the expression and degradation of specific mitogen-activated protein Kinase phosphatases in bovine granulosa cells. Mol Endocrinol 22: 2655-2676.
36. Shang Y, Brown M. (2002). Molecular determinants for the tissue specificity of SERMs. Science 295: 2465-2468. (Pubitemid 34270263)
37. Taylor AH, Ang VT, JenKins JS, Silverlight JJ, Coombes RC, Luqmani YA. (1990). Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res 50: 7882-7886.
38. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF et al. (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl JMed 353: 2747-2757. (Pubitemid 43016814)
39. Van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536. (Pubitemid 34130608)
40. Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S et al. (2008). Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. Endocr Relat Cancer 15: 755-763.
41. Zoubir M, Mathieu MC, Mazouni C, Liedtke C, Corley L, Geha S et al. (2008). Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. Ann Oncol 19: 1402-1406.
42. ZujewsKi JA, Kamin L. (2008). Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol 4: 603-610.
43. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ, Bernards R. (1998). Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 12: 3488-3498. (Pubitemid 28553241)